The global skin cancer diagnostics market size was valued at USD 9.62 billion in 2024 and is projected to hit USD 10.18 billion in 2025 to reach around USD 16.91 billion by 2034, growing at a CAGR of 5.8% from 2025 to 2034. The skin cancer diagnostics market is growing due to the rising incidence of melanoma and non-melanoma cancers, increased UV exposure, and an aging global population. Advancements in diagnostic technologies such as non-invasive imaging, dermatoscopy, and AI-based detection tools are improving early diagnosis and expanding adoption.
The global skin cancer diagnostics market is witnessing steady growth, driven by the rising prevalence of melanoma and non-melanoma cancers, increasing awareness of early detection, and advancements in dermatological imaging technologies. Growing adoption of AI-enabled diagnostic tools, dermatoscopy devices, and non-invasive screening methods is significantly enhancing accuracy and clinical outcomes.
Additionally, expanding healthcare infrastructure, favorable reimbursement policies, and increasing routine skin screening programs are supporting wider diagnosis rates. However, high device costs, limited access to skilled dermatologists in emerging regions, and variability in diagnostic accuracy across modalities remain key challenges. Overall, the market is positioned for continued expansion as early detection becomes a global priority and technological innovation accelerates.
The growth of the skin cancer diagnostics market is propelled by the increasing incidence of skin cancer worldwide, driven by factors such as prolonged UV exposure and aging populations, is significantly boosting the demand for effective diagnostic solutions. Technological advancements in diagnostic tools, including non-invasive imaging techniques and AI-driven diagnostic algorithms, are enhancing early detection and accuracy, thereby expanding the market. Additionally, growing public awareness and educational campaigns about the importance of early skin cancer detection are encouraging more individuals to seek regular screenings. Government initiatives and funding for skin cancer research further support the development and adoption of innovative diagnostic methods.
| Report Coverage | Details |
| Market Size in 2024 | USD 9.62 Billion |
| Revenue Forecast by 2034 | USD 16.91 Billion |
| Growth rate from 2025 to 2034 | CAGR of 5.8% |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Regions | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Castle Bioscience, DermTech, bioMérieux Inc., FOUNDATION MEDICINE, INC., DermaSensor, Inc., F. Hoffmann-La Roche Ltd, NeoGenomics Laboratories, Quest Diagnostics Incorporated, SkylineDx, Abbott |
In 2024, the North American skin cancer diagnostics market accounted for a 41% share. Skin cancer is the most prevalent form of cancer in the U.S., with approximately one in five individuals expected to suffer from skin cancer in their lifetime. An estimated 9,500 individuals in the U.S. receive a skin cancer diagnosis daily. NMSC, including BCC and SCC, affects over 3 million U.S. citizens annually. Additionally, strategic initiatives undertaken by key market players offer lucrative opportunities for market growth over the forecast period. In May 2024, Epredia, a subsidiary of PHC Holdings Corporation, partnered with NovaScan, Inc. to sign a letter of intent for an exclusive commercial distribution agreement in the U.S. for MarginScan. This medical device is designed to aid physicians in the real-time detection of NMSC, driving innovation and providing a wide range of products to meet market demand.
The Asia Pacific is anticipated to witness the fastest growth in the skin cancer diagnostics market, driven by increasing awareness of skin cancer, rising incidences due to environmental factors such as UV exposure, and advancements in diagnostic technologies. Growing healthcare expenditure and improved access to medical facilities also contribute to market growth, along with government initiatives promoting early detection and treatment of skin cancer.
On the basis of cancer type, the nonmelanoma segment held the largest market share of 75% in 2024. The rising incidence of Nonmelanoma Skin Cancer (NMSC) is a significant driver for novel technologies in screening and diagnosis. Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), which make up 70% and 25% of NMSC cases respectively, are the most prevalent forms of skin cancer, accounting for 90% of all malignant skin tumors. Studies predict a continued increase in NMSC cases until at least 2040, underscoring the urgent need for reliable screening tools.
Additionally, deep learning, a form of AI, shows promise in image analysis and is particularly attractive for NMSC diagnosis. As NMSC cases rise globally, there is a growing demand for early detection tools. Deep learning has emerged as a valuable decision-support tool in medicine, offering significant potential in image analysis, a critical aspect of dermatology diagnoses. Dermatology heavily relies on visual diagnoses, making deep learning’s image analysis capabilities highly relevant for diagnosing skin cancer. With the widespread availability of smartphones equipped with powerful cameras, deep learning technology can also be leveraged for remote skin cancer screening. Current data indicates that deep learning technology for detecting and diagnosing cancer offers sensitivity and specificity comparable to trained dermatologists.
In 2024, skin biopsy led the skin cancer diagnostics market with a market share of 32%. Skin biopsy is a fundamental diagnostic procedure in dermatology, with various methods available for different situations. Factors such as lesion type, location, and suspected diagnosis influence the choice of biopsy technique. Histopathologic evaluation remains the gold standard for diagnosing skin cancer, providing crucial information for treatment planning and prognosis.
The imaging tests segment is expected to grow at the fastest CAGR during the forecast period. Emerging optical imaging modalities, including Reflectance Confocal Microscopy (RCM), Optical Coherence Tomography (OCT), Magnetic Resonance Imaging (MRI), Near-infrared (NIR) bioimaging, and Positron Emission Tomography (PET), offer noninvasive imaging data that can aid in the early detection of cutaneous tumors and assist in surgical planning. These modalities are valuable for observing dynamic processes, such as blood flow, immune cell activation, and tumor energy metabolism, which are relevant for disease progression.
Hospitals and clinics led the skin cancer diagnostics market with a market share of 54% in 2024. Additionally, this segment is expected to be the fastest-growing over the forecast period. Its growth can be attributed to the increasing incidence of skin cancer, advancements in diagnostic technologies, and rising awareness about early detection. The integration of AI and teledermatology in hospitals can further enhance diagnostic accuracy and accessibility, boosting the demand for hospital-based skin cancer diagnostic services.
In May 2023, the UK NHS planned to accelerate the rollout of teledermatology, which involves taking high-resolution images of skin spots, moles, or lesions for faster diagnosis and treatment of skin cancer. This technology uses a small lens attached to a phone camera (dermatoscope), allowing dermatologists to double the number of patients they can review daily. Teledermatology, currently used in about 15% of trusts offering dermatology services, was expected to be available in all areas by July 2023. It would also be expanded to GP practices, aiding people in rural areas and reducing the need for specialist appointments. More than 600,000 people were referred for skin cancer checks last year, a 9% increase from the previous year.
NHS trusts are expanding the use of teledermatology in community diagnostic centers to reduce waiting times. Patients can be referred directly to a local diagnostic hub, avoiding the need for a face-to-face appointment. Additionally, magnifying lenses using AI technology are being trialed to assess lesions quickly and accurately. This technology has helped avoid around 10,000 unnecessary face-to-face appointments. Moreover, it has enabled some hospitals to diagnose and treat virtually all skin cancer patients within 2 months of GP referral. The NHS's focus on technology-driven advancements in cancer diagnosis and treatment is expected to significantly improve patient outcomes and reduce the burden on healthcare resources.
By Cancer Type
By Test Type
By End-use
By Region
Skin Cancer Diagnostics Market
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Cancer Type Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Skin Cancer Diagnostics Market
5.1. COVID-19 Landscape: Skin Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Skin Cancer Diagnostics Market, By Cancer Type
8.1. Skin Cancer Diagnostics Market, by Cancer Type
8.1.1 Melanoma
8.1.1.1. Market Revenue and Forecast
8.1.2. Non-Melanoma
8.1.2.1. Market Revenue and Forecast
Chapter 9. Global Skin Cancer Diagnostics Market, By Test Type
9.1. Skin Cancer Diagnostics Market, by Test Type
9.1.1. Dermatoscopy
9.1.1.1. Market Revenue and Forecast
9.1.2. Skin Biopsy
9.1.2.1. Market Revenue and Forecast
9.1.3. Lymph Node Biopsy
9.1.3.1. Market Revenue and Forecast
9.1.4. Imaging Tests
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
Chapter 10. Global Skin Cancer Diagnostics Market, By March
10.1. Skin Cancer Diagnostics Market, by March
10.1.1. Hospital and Clinics
10.1.1.1. Market Revenue and Forecast
10.1.2. Laboratories
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
Chapter 11. Global Skin Cancer Diagnostics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Cancer Type
11.1.2. Market Revenue and Forecast, by Test Type
11.1.3. Market Revenue and Forecast, by March
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Cancer Type
11.1.4.2. Market Revenue and Forecast, by Test Type
11.1.4.3. Market Revenue and Forecast, by March
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Cancer Type
11.1.5.2. Market Revenue and Forecast, by Test Type
11.1.5.3. Market Revenue and Forecast, by March
11.2. Europe
11.2.1. Market Revenue and Forecast, by Cancer Type
11.2.2. Market Revenue and Forecast, by Test Type
11.2.3. Market Revenue and Forecast, by March
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Cancer Type
11.2.4.2. Market Revenue and Forecast, by Test Type
11.2.4.3. Market Revenue and Forecast, by March
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Cancer Type
11.2.5.2. Market Revenue and Forecast, by Test Type
11.2.5.3. Market Revenue and Forecast, by March
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Cancer Type
11.2.6.2. Market Revenue and Forecast, by Test Type
11.2.6.3. Market Revenue and Forecast, by March
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Cancer Type
11.2.7.2. Market Revenue and Forecast, by Test Type
11.2.7.3. Market Revenue and Forecast, by March
11.3. APAC
11.3.1. Market Revenue and Forecast, by Cancer Type
11.3.2. Market Revenue and Forecast, by Test Type
11.3.3. Market Revenue and Forecast, by March
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Cancer Type
11.3.4.2. Market Revenue and Forecast, by Test Type
11.3.4.3. Market Revenue and Forecast, by March
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Cancer Type
11.3.5.2. Market Revenue and Forecast, by Test Type
11.3.5.3. Market Revenue and Forecast, by March
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Cancer Type
11.3.6.2. Market Revenue and Forecast, by Test Type
11.3.6.3. Market Revenue and Forecast, by March
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Cancer Type
11.3.7.2. Market Revenue and Forecast, by Test Type
11.3.7.3. Market Revenue and Forecast, by March
11.4. MEA
11.4.1. Market Revenue and Forecast, by Cancer Type
11.4.2. Market Revenue and Forecast, by Test Type
11.4.3. Market Revenue and Forecast, by March
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Cancer Type
11.4.4.2. Market Revenue and Forecast, by Test Type
11.4.4.3. Market Revenue and Forecast, by March
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Cancer Type
11.4.5.2. Market Revenue and Forecast, by Test Type
11.4.5.3. Market Revenue and Forecast, by March
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Cancer Type
11.4.6.2. Market Revenue and Forecast, by Test Type
11.4.6.3. Market Revenue and Forecast, by March
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Cancer Type
11.4.7.2. Market Revenue and Forecast, by Test Type
11.4.7.3. Market Revenue and Forecast, by March
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Cancer Type
11.5.2. Market Revenue and Forecast, by Test Type
11.5.3. Market Revenue and Forecast, by March
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Cancer Type
11.5.4.2. Market Revenue and Forecast, by Test Type
11.5.4.3. Market Revenue and Forecast, by March
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Cancer Type
11.5.5.2. Market Revenue and Forecast, by Test Type
11.5.5.3. Market Revenue and Forecast, by March
Chapter 12. Company Profiles
12.1. Castle Bioscience.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. DermTech.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. bioMérieux Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. FOUNDATION MEDICINE, INC.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. DermaSensor, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. F Hoffmann-La Roche Ltd
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. NeoGenomics Laboratories.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Quest Diagnostics Incorporated.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. SkylineDx
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers